Next Article in Journal
The Role of Non-Selective β-Blockers in Compensated Cirrhotic Patients without Major Complications
Previous Article in Journal
Splenectomy in Lymphoproliferative Disorders: A Single Eastern European Center Experience
Open AccessCase Report

Possible Interaction between Dabigatran and Ranolazine in Patients with Renal Failure

1
Division of Clinical Pharmacology, Institute of Physiology and Pharmacology, Medical Academy, Lithuanian University of Health Sciences, 44307 Kaunas, Lithuania
2
Department of Internal Medicine, Kaunas Clinical Hospital, 44127 Kaunas, Lithuania
3
Department of Geriatrics, Medical Academy, Lithuanian University of Health Sciences, 44307 Kaunas, Lithuania
4
Department of Geriatrics, Kaunas Clinical Hospital, 44127 Kaunas, Lithuania
*
Author to whom correspondence should be addressed.
Medicina 2020, 56(1), 13; https://doi.org/10.3390/medicina56010013
Received: 3 December 2019 / Revised: 23 December 2019 / Accepted: 24 December 2019 / Published: 29 December 2019
Dabigatran etexilate is a direct oral anticoagulant (thrombin inhibitor) used for the prevention of stroke and systemic thromboembolic events in patients with permanent atrial fibrillation; prevention of venous thromboembolic events and deep veins thrombosis; treatment and prevention of pulmonary embolism. Dabigatran is a relatively new drug, and as a result, its interactions with other medications and their significance are not fully known. A 72 years old male, having a medical history of heart and renal failure, was hospitalized for pneumonia treatment. The patient was taking several drugs, including dabigatran 150 mg twice daily and ranolazine 750 mg twice daily. His creatinine clearance was 45.22 mL/min, International Normalized Ratio (INR)—7.03. Dabigatran was discontinued. After 9 days, INR decreased to 1.33, and after 6 days, creatinine clearance increased to 64.39 mL/min. The patient was taking an adequate dosage of dabigatran, thus dabigatran was thought to be overdosed due to its interaction with ranolazine because dabigatran is a p-glycoprotein substrate, whereas ranolazine is the inhibitor of this transporter. Dabigatran and ranolazine should be used with caution in patients with renal failure. It is recommended to use smaller doses of both medications and observe coagulation parameters if needed. View Full-Text
Keywords: anticoagulants; dabigatran; ranolazine; drugs interaction; renal failure anticoagulants; dabigatran; ranolazine; drugs interaction; renal failure
MDPI and ACS Style

Gumbrevičius, G.; Damulevičienė, G.; Galaunė, V.; Gumbrevičiūtė, M. Possible Interaction between Dabigatran and Ranolazine in Patients with Renal Failure. Medicina 2020, 56, 13.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop